What is Sandoz Group AG Price-to-Owner-Earnings?
As of today (2024-05-25), Sandoz Group AG's share price is $34.995.
Sandoz Group AG does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.
The historical rank and industry rank for Sandoz Group AG's Price-to-Owner-Earnings or its related term are showing as below:
As of today (2024-05-25), Sandoz Group AG's share price is $34.995.
Sandoz Group AG does not have enough years/quarters to calculate the Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023. Therefore GuruFocus does not calculate PE Ratio at this moment.
As of today (2024-05-25), Sandoz Group AG's share price is $34.995.
Sandoz Group AG does not have enough years/quarters to calculate the EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023. Therefore GuruFocus does not calculate PE Ratio without NRI at this moment.
During the past 2 years, Sandoz Group AG's highest PE Ratio without NRI was 193.75. The lowest was 0.00. And the median was 0.00.
Sandoz Group AG Price-to-Owner-Earnings Historical Data
The historical data trend for Sandoz Group AG's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG Price-to-Owner-Earnings Chart
|
Sandoz Group AG Annual Data
|
|
Trend |
Dec22 |
Dec23 |
| Price-to-Owner-Earnings |
|
- |
- |
|
Sandoz Group AG Quarterly Data
|
|
Dec22 |
Dec23 |
| Price-to-Owner-Earnings |
- |
- |
Competitive Comparison of Sandoz Group AG's Price-to-Owner-Earnings
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Price-to-Owner-Earnings falls into.
Sandoz Group AG Price-to-Owner-Earnings Calculation
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Sandoz Group AG's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (Sandoz Group AG) Business Description
Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.
Sandoz Group AG (Sandoz Group AG) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SDZNY has been successfully added to your